Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Apeiron Synthesis has successfully commercialized its proprietary olefin metathesis catalyst technology, which has been implemented industrially by at least four customers. Applications include API production for next-generation diabetes drugs, pheromones for crop protection, synthetic musks for fragrances, and functional polymers. The use of their catalysts can reduce process steps in drug manufacturing by up to four stages and lower costs by about 20%.
No clinical trial results are reported since the company does not develop therapeutics itself but enables others' development.Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Apeiron Synthesis.